

Applicant(s) **David FIKSTAD, et al.**

| | |
|------------------------------------|-----------------------------|
| Filing Date: March 19, 2001 | Group Art Unit: 1676 |
|------------------------------------|-----------------------------|

| Examiner Initials | Ref. Number | Date | Document No. | Name | Class | Subclass | Filing Date (if appropriate) |
|----------------------|----------------|------|--------------|------|-------|----------|---------------------------------|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Translation | |
|----------------------|-------------|-----------|--------------|----------------------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| <i>Ph</i> | 1. | 12/6/2000 | EP 1057480A2 | Pfizer Products Inc. | | | | |
| <i>Ph</i> | 2. | 7/18/1996 | WO 96/21656 | Pfizer, Inc. | | | | |

(including author, title, date, pertinent pages, etc.)

[illegible]

**COPY OF PAPERS
ORIGINALLY FILED**

EXAMINER: M. J. Jones DATE CONSIDERED: 11/02/02

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.